Published in Women's Health Weekly, October 10th, 2002
As of June 30, 2002, the Novogen Group had $22 million in cash reserves compared with $17 million for the previous corresponding period.
This was coupled with a 33% reduction of the net loss for the 12 months to $8.0 million, down from $11.9 million for the year ended June 30, 2001.
Directors said the cash boost to the group was achieved through a stringent cost-control program and the successful listing and financing in May 2002, of U.S. incorporated subsidiary Marshall Edwards, Inc., on the London Stock...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly